Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202154 | 0.91 | CYP11B1 (0.40) | CYP11B1CYP11B2SIRT2SMN1; SMN2KDM4E | |
| SCHEMBL5688715 | 0.85 | SIRT2 (0.40) | CYP11B1CYP11B2SIRT2ENPP2CYP19A1 | |
| SCHEMBL2787652 | 0.82 | CYP19A1 (0.36) | CYP11B1CYP11B2CYP19A1CYP3A4MEN1 | |
| SCHEMBL2787655 | 0.82 | CYP19A1 (0.36) | CYP11B1CYP11B2CYP19A1CYP3A4MEN1 | |
| SCHEMBL21636129 | 0.79 | SIRT2 (0.35) | CYP11B1CYP11B2SIRT2ENPP2CYP19A1 | |
| SCHEMBL7668744 | 0.79 | SIRT2 (0.37) | CYP11B1CYP11B2SIRT2LMNAACHE | |
| SCHEMBL1039275 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2ENPP2KMT2A | |
| SCHEMBL12887208 | 0.77 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2ENPP2KMT2A | |
| SCHEMBL17651947 | 0.77 | SIRT2 (0.36) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL3789168 | 0.76 | CYP11B1 (0.36) | CYP11B1CYP11B2SIRT2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102481292-A | Novel pharmaceutically acceptable salts of 4- (1H-imidazol-4-ylmethyl) pyridine and their therapeutic applications | BIOPROJET SOC CIV | 2012-05-30 | — | — | CN | disclosed |
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2432469-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2012-03-28 | — | — | EP | disclosed |
| EP-2263672-A1 | Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses | BIOPROJET (FR) | 2010-12-22 | — | — | EP | disclosed |
| EP-2263672-A1 | Novel pharmaceutically acceptable salts of 4-(1H-imidazol-4-ylmethyl)pyridine and their therapeutical uses | BIOPROJET (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010133598-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133598-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | BIOPROJET (FR) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129892-A1 | NOVEL PHARMACEUTICALLY ACCEPTABLE SALTS OF 4-(1H-IMIDAZOL-4-YLMETHYL)PYRIDINE AND THEIR THERAPEUTICAL USES | DPP4, PDE8A, PDE8B | CYP11B1 635/4885CYP11B2 359/4885SIRT2 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.